A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer
Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and cara...
Gespeichert in:
| Veröffentlicht in: | Investigational new drugs 1996-01, Vol.14 (4), p.409-413 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 413 |
|---|---|
| container_issue | 4 |
| container_start_page | 409 |
| container_title | Investigational new drugs |
| container_volume | 14 |
| creator | WITTE, R. S HSIEH, P ELSON, P OKEN, M. M TRUMP, D. L |
| description | Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and caracemide were well tolerated with no unexpected toxicities. One patient each died of pulmonary thromboembolism and sepsis with severe metabolic acidosis on the homoharringtonine arm. An additional 4 patients experienced grade 4 complications including myelosuppression, neurologic dysfunction, and respiratory failure. These severe and unexpected complications caused early termination of accrual to the homoharringtonine arm of the study. These agents have no activity in the treatment of advanced renal cell carcinoma. |
| doi_str_mv | 10.1007/BF00180819 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00180819</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9157078</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-927d5eaaf279ad3d170e4055a303f0e14886f4f88e5b2ca441e15c21a798d3563</originalsourceid><addsrcrecordid>eNpFkEFPwzAMhSMEGmNw4Y6UAydEwWnapj3CxGDSJC5wrrzEoUFrOiUFxIH_TsemcbEt-_Oz_Bg7F3AjANTt_QxAlFCK6oCNRa5kAkVWHLIxiEIlRVWpY3YS4zsAyEplIzaqBgpUOWY_d3zdYCQ-n_M-OFzxznJsO4_WGbrmGgNqav9q9IY3Xds1GILzb33nnSfuPO8bGpYJ-5Z8vxFYY--GMvIv1zcczSd6TYYH8sMBTashbDrhlB1ZXEU62-UJe509vEyfksXz43x6t0i0FKJPqlSZnBBtqio00ggFlEGeowRpgURWloXNbFlSvkw1ZpkgketUoKpKI_NCTtjVVleHLsZAtl4H12L4rgXUGwvrfwsH-GILrz-WLZk9uvNsmF_u5hg1rmwYXnFxj6UqVTIV8hddzHiR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>WITTE, R. S ; HSIEH, P ; ELSON, P ; OKEN, M. M ; TRUMP, D. L</creator><creatorcontrib>WITTE, R. S ; HSIEH, P ; ELSON, P ; OKEN, M. M ; TRUMP, D. L</creatorcontrib><description>Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and caracemide were well tolerated with no unexpected toxicities. One patient each died of pulmonary thromboembolism and sepsis with severe metabolic acidosis on the homoharringtonine arm. An additional 4 patients experienced grade 4 complications including myelosuppression, neurologic dysfunction, and respiratory failure. These severe and unexpected complications caused early termination of accrual to the homoharringtonine arm of the study. These agents have no activity in the treatment of advanced renal cell carcinoma.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/BF00180819</identifier><identifier>PMID: 9157078</identifier><identifier>CODEN: INNDDK</identifier><language>eng</language><publisher>Dordrecht: Kluwer</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Renal Cell - drug therapy ; Chemotherapy ; Female ; Harringtonines - administration & dosage ; Humans ; Hydroxyurea - administration & dosage ; Hydroxyurea - analogs & derivatives ; Imides - administration & dosage ; Isoquinolines - administration & dosage ; Kidney Neoplasms - drug therapy ; Male ; Medical sciences ; Middle Aged ; Naphthalimides ; Pharmacology. Drug treatments ; Survival Rate ; Treatment Outcome</subject><ispartof>Investigational new drugs, 1996-01, Vol.14 (4), p.409-413</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-927d5eaaf279ad3d170e4055a303f0e14886f4f88e5b2ca441e15c21a798d3563</citedby><cites>FETCH-LOGICAL-c311t-927d5eaaf279ad3d170e4055a303f0e14886f4f88e5b2ca441e15c21a798d3563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2727321$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9157078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WITTE, R. S</creatorcontrib><creatorcontrib>HSIEH, P</creatorcontrib><creatorcontrib>ELSON, P</creatorcontrib><creatorcontrib>OKEN, M. M</creatorcontrib><creatorcontrib>TRUMP, D. L</creatorcontrib><title>A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and caracemide were well tolerated with no unexpected toxicities. One patient each died of pulmonary thromboembolism and sepsis with severe metabolic acidosis on the homoharringtonine arm. An additional 4 patients experienced grade 4 complications including myelosuppression, neurologic dysfunction, and respiratory failure. These severe and unexpected complications caused early termination of accrual to the homoharringtonine arm of the study. These agents have no activity in the treatment of advanced renal cell carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Harringtonines - administration & dosage</subject><subject>Humans</subject><subject>Hydroxyurea - administration & dosage</subject><subject>Hydroxyurea - analogs & derivatives</subject><subject>Imides - administration & dosage</subject><subject>Isoquinolines - administration & dosage</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Naphthalimides</subject><subject>Pharmacology. Drug treatments</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEFPwzAMhSMEGmNw4Y6UAydEwWnapj3CxGDSJC5wrrzEoUFrOiUFxIH_TsemcbEt-_Oz_Bg7F3AjANTt_QxAlFCK6oCNRa5kAkVWHLIxiEIlRVWpY3YS4zsAyEplIzaqBgpUOWY_d3zdYCQ-n_M-OFzxznJsO4_WGbrmGgNqav9q9IY3Xds1GILzb33nnSfuPO8bGpYJ-5Z8vxFYY--GMvIv1zcczSd6TYYH8sMBTashbDrhlB1ZXEU62-UJe509vEyfksXz43x6t0i0FKJPqlSZnBBtqio00ggFlEGeowRpgURWloXNbFlSvkw1ZpkgketUoKpKI_NCTtjVVleHLsZAtl4H12L4rgXUGwvrfwsH-GILrz-WLZk9uvNsmF_u5hg1rmwYXnFxj6UqVTIV8hddzHiR</recordid><startdate>19960101</startdate><enddate>19960101</enddate><creator>WITTE, R. S</creator><creator>HSIEH, P</creator><creator>ELSON, P</creator><creator>OKEN, M. M</creator><creator>TRUMP, D. L</creator><general>Kluwer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19960101</creationdate><title>A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer</title><author>WITTE, R. S ; HSIEH, P ; ELSON, P ; OKEN, M. M ; TRUMP, D. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-927d5eaaf279ad3d170e4055a303f0e14886f4f88e5b2ca441e15c21a798d3563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Harringtonines - administration & dosage</topic><topic>Humans</topic><topic>Hydroxyurea - administration & dosage</topic><topic>Hydroxyurea - analogs & derivatives</topic><topic>Imides - administration & dosage</topic><topic>Isoquinolines - administration & dosage</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Naphthalimides</topic><topic>Pharmacology. Drug treatments</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WITTE, R. S</creatorcontrib><creatorcontrib>HSIEH, P</creatorcontrib><creatorcontrib>ELSON, P</creatorcontrib><creatorcontrib>OKEN, M. M</creatorcontrib><creatorcontrib>TRUMP, D. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WITTE, R. S</au><au>HSIEH, P</au><au>ELSON, P</au><au>OKEN, M. M</au><au>TRUMP, D. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>1996-01-01</date><risdate>1996</risdate><volume>14</volume><issue>4</issue><spage>409</spage><epage>413</epage><pages>409-413</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><coden>INNDDK</coden><abstract>Forty-eight previously untreated, ambulatory patients with advanced or unresectable renal carcinoma were treated with either amonafide (17 patients), caracemide (17 patients), or homoharringtonine (14 patients). No objective responses were observed in any of the treatment cohorts. Amonafide and caracemide were well tolerated with no unexpected toxicities. One patient each died of pulmonary thromboembolism and sepsis with severe metabolic acidosis on the homoharringtonine arm. An additional 4 patients experienced grade 4 complications including myelosuppression, neurologic dysfunction, and respiratory failure. These severe and unexpected complications caused early termination of accrual to the homoharringtonine arm of the study. These agents have no activity in the treatment of advanced renal cell carcinoma.</abstract><cop>Dordrecht</cop><pub>Kluwer</pub><pmid>9157078</pmid><doi>10.1007/BF00180819</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6997 |
| ispartof | Investigational new drugs, 1996-01, Vol.14 (4), p.409-413 |
| issn | 0167-6997 1573-0646 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00180819 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Renal Cell - drug therapy Chemotherapy Female Harringtonines - administration & dosage Humans Hydroxyurea - administration & dosage Hydroxyurea - analogs & derivatives Imides - administration & dosage Isoquinolines - administration & dosage Kidney Neoplasms - drug therapy Male Medical sciences Middle Aged Naphthalimides Pharmacology. Drug treatments Survival Rate Treatment Outcome |
| title | A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T19%3A42%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20trial%20of%20amonafide,%20caracemide,%20and%20homoharringtonine%20in%20the%20treatment%20of%20patients%20with%20advanced%20renal%20cell%20cancer&rft.jtitle=Investigational%20new%20drugs&rft.au=WITTE,%20R.%20S&rft.date=1996-01-01&rft.volume=14&rft.issue=4&rft.spage=409&rft.epage=413&rft.pages=409-413&rft.issn=0167-6997&rft.eissn=1573-0646&rft.coden=INNDDK&rft_id=info:doi/10.1007/BF00180819&rft_dat=%3Cpubmed_cross%3E9157078%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9157078&rfr_iscdi=true |